208. Dextromethorphan-Quinidine in Treatment-Resistant Depression: An Open-Label Pilot Study

Philip Wang,Mani Yavi,Lawrence Park,Carlos Zarate

Biological Psychiatry（2023）

引用 0|浏览0

暂无评分

摘要

Approximately one third of patients with major depressive disorder have treatment-resistant depression (TRD). Drugs that target the glutamatergic system, such as the NMDA receptor (NMDAR) antagonist ketamine, have been shown to lead to rapid and robust antidepressant effects, but are limited by accessibility and route of administration.

查看译文

关键词

Clinical Trials, NMDA antagonists, Treatment Resistant Depression, Psychopharmacological Treatment, Dextromethorphan

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要